J Kevin Buchi - Net Worth and Insider Trading

J Kevin Buchi Net Worth

The estimated net worth of J Kevin Buchi is at least $788,106 dollars as of 2024-12-27. J Kevin Buchi is the Director of Benitec Biopharma Inc and owns about 52,097 shares of Benitec Biopharma Inc (BNTC) stock worth over $625,164. J Kevin Buchi is the Director of Stemline Therapeutics Inc and owns about 13,772 shares of Stemline Therapeutics Inc (STML) stock worth over $162,923. J Kevin Buchi is also the Director of Ampio Pharmaceuticals Inc and owns about 7,343 shares of Ampio Pharmaceuticals Inc (AMPE) stock worth over $19. Details can be seen in J Kevin Buchi's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that J Kevin Buchi has not made any transactions after 2023-08-11 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of J Kevin Buchi

J Kevin Buchi Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, J Kevin Buchi owns 10 companies in total, including Alaunos Therapeutics Inc (TCRT) , Dicerna Pharmaceuticals Inc (DRNA) , and Amneal Pharmaceuticals Inc (AMRX) among others .

Click here to see the complete history of J Kevin Buchi’s form 4 insider trades.

Insider Ownership Summary of J Kevin Buchi

Ticker	Comapny	Transaction Date	Type of Owner
TCRT	Alaunos Therapeutics Inc	2020-09-21	director
DRNA	Dicerna Pharmaceuticals Inc	2020-06-15	director
AMRX	Amneal Pharmaceuticals Inc	2018-05-04	director
		2023-08-11	director
		2019-10-23	director & Chief Executive Officer
		2016-06-21	director
		2015-06-23	director
		2015-06-05	director
		2015-03-26	director & President & CEO
		2023-06-09	director

J Kevin Buchi Latest Holdings Summary

J Kevin Buchi currently owns a total of 3 stocks. Among these stocks, J Kevin Buchi owns 52,097 shares of Benitec Biopharma Inc (BNTC) as of August 11, 2023, with a value of $625,164 and a weighting of 79.32%. J Kevin Buchi owns 13,772 shares of Stemline Therapeutics Inc (STML) as of January 29, 2013, with a value of $162,923 and a weighting of 20.67%. J Kevin Buchi also owns 7,343 shares of Ampio Pharmaceuticals Inc (AMPE) as of June 9, 2023, with a value of $19 and a weighting of 0%.

Latest Holdings of J Kevin Buchi

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
BNTC	Benitec Biopharma Inc	2023-08-11	52,097	12.00	625,164
STML	Stemline Therapeutics Inc	2013-01-29	13,772	11.83	162,923
AMPE	Ampio Pharmaceuticals Inc	2023-06-09	7,343	0.00	19

Holding Weightings of J Kevin Buchi

J Kevin Buchi Form 4 Trading Tracker

According to the SEC Form 4 filings, J Kevin Buchi has made a total of 1 transactions in Benitec Biopharma Inc (BNTC) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Benitec Biopharma Inc is the acquisition of 51,813 shares on August 11, 2023, which cost J Kevin Buchi around $145,595.

According to the SEC Form 4 filings, J Kevin Buchi has made a total of 0 transactions in Stemline Therapeutics Inc (STML) over the past 5 years. The most-recent trade in Stemline Therapeutics Inc is the acquisition of 500 shares on January 29, 2013, which cost J Kevin Buchi around $5,000.

According to the SEC Form 4 filings, J Kevin Buchi has made a total of 4 transactions in Ampio Pharmaceuticals Inc (AMPE) over the past 5 years, including 4 buys and 0 sells. The most-recent trade in Ampio Pharmaceuticals Inc is the acquisition of 1,093 shares on June 9, 2023, which cost J Kevin Buchi around $6,339.

Insider Trading History of J Kevin Buchi

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

J Kevin Buchi Trading Performance

GuruFocus tracks the stock performance after each of J Kevin Buchi's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by J Kevin Buchi is -9.26%. GuruFocus also compares J Kevin Buchi's trading performance to market benchmark return within the same time period. The performance of stocks bought by J Kevin Buchi within 3 months outperforms 2 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how J Kevin Buchi's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of J Kevin Buchi

Average Return

Average return per transaction

Outperforming Transactions

2 out of 6 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-3.9
Relative Return to S&P 500(%)	-7.28

J Kevin Buchi Ownership Network

Ownership Network List of J Kevin Buchi

No Data

Ownership Network Relation of J Kevin Buchi

J Kevin Buchi Owned Company Details

What does Alaunos Therapeutics Inc do?

Who are the key executives at Alaunos Therapeutics Inc?

J Kevin Buchi is the director of Alaunos Therapeutics Inc. Other key executives at Alaunos Therapeutics Inc include director & Chief Executive Officer Boyle Kevin S. Sr. , VP & Finance Michael Wong , and See Remarks Abhishek K Srivastava .

Alaunos Therapeutics Inc (TCRT) Insider Trades Summary

Over the past 18 months, J Kevin Buchi made no insider transaction in Alaunos Therapeutics Inc (TCRT). Other recent insider transactions involving Alaunos Therapeutics Inc (TCRT) include a net sale of 68,014 shares made by Boyle Kevin S. Sr. ,

In summary, during the past 3 months, insiders sold 0 shares of Alaunos Therapeutics Inc (TCRT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 453 shares of Alaunos Therapeutics Inc (TCRT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 453 shares.

Alaunos Therapeutics Inc (TCRT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alaunos Therapeutics Inc Insider Transactions

No Available Data

What does Dicerna Pharmaceuticals Inc do?

Who are the key executives at Dicerna Pharmaceuticals Inc?

J Kevin Buchi is the director of Dicerna Pharmaceuticals Inc. Other key executives at Dicerna Pharmaceuticals Inc include See Remarks Bob D Brown , EVP & Chief Medical Officer Shreeram Aradhye , and director & President and CEO Douglas Fambrough .

Dicerna Pharmaceuticals Inc (DRNA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Dicerna Pharmaceuticals Inc (DRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Dicerna Pharmaceuticals Inc (DRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Dicerna Pharmaceuticals Inc (DRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dicerna Pharmaceuticals Inc Insider Transactions

No Available Data

What does Amneal Pharmaceuticals Inc do?

Who are the key executives at Amneal Pharmaceuticals Inc?

J Kevin Buchi is the director of Amneal Pharmaceuticals Inc. Other key executives at Amneal Pharmaceuticals Inc include SVP & Chief Legal Officer Jason B. Daly , Exec VP & Comm Optns Andrew S Boyer , and SVP & Chief HR Officer Nikita Shah .

Amneal Pharmaceuticals Inc (AMRX) Insider Trades Summary

Over the past 18 months, J Kevin Buchi made no insider transaction in Amneal Pharmaceuticals Inc (AMRX). Other recent insider transactions involving Amneal Pharmaceuticals Inc (AMRX) include a net sale of 92,013 shares made by Andrew S Boyer , a net sale of 78,000 shares made by Deborah M. Autor , and a net sale of 57,322 shares made by Jason B. Daly .

In summary, during the past 3 months, insiders sold 114,380 shares of Amneal Pharmaceuticals Inc (AMRX) in total and bought 0 shares, with a net sale of 114,380 shares. During the past 18 months, 344,393 shares of Amneal Pharmaceuticals Inc (AMRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 344,393 shares.

Amneal Pharmaceuticals Inc (AMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Amneal Pharmaceuticals Inc Insider Transactions

No Available Data

What does Benitec Biopharma Inc do?

Who are the key executives at Benitec Biopharma Inc?

J Kevin Buchi is the director of Benitec Biopharma Inc. Other key executives at Benitec Biopharma Inc include director & Executive Director Megan Boston , 10 percent owner Steven Michael Oliveira , and 10 percent owner Patrick Soon-shiong .

Benitec Biopharma Inc (BNTC) Insider Trades Summary

Over the past 18 months, J Kevin Buchi made 1 insider transaction in Benitec Biopharma Inc (BNTC) with a net purchase of 51,813. Other recent insider transactions involving Benitec Biopharma Inc (BNTC) include a net purchase of 130,956 shares made by , a net purchase of 25,907 shares made by Megan Boston ,

In summary, during the past 3 months, insiders sold 0 shares of Benitec Biopharma Inc (BNTC) in total and bought 130,956 shares, with a net purchase of 130,956 shares. During the past 18 months, 0 shares of Benitec Biopharma Inc (BNTC) were sold and 208,676 shares were bought by its insiders, resulting in a net purchase of 208,676 shares.

Benitec Biopharma Inc (BNTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Benitec Biopharma Inc Insider Transactions

No Available Data

What does BioSpecifics Technologies Corp do?

Who are the key executives at BioSpecifics Technologies Corp?

J Kevin Buchi is the director & Chief Executive Officer of BioSpecifics Technologies Corp. Other key executives at BioSpecifics Technologies Corp include director & 10 percent owner Toby Wegman , director & Chief Executive Officer Joseph Truitt , and Chief Financial Officer Patrick Hutchison .

BioSpecifics Technologies Corp (BSTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioSpecifics Technologies Corp (BSTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioSpecifics Technologies Corp (BSTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioSpecifics Technologies Corp (BSTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioSpecifics Technologies Corp Insider Transactions

No Available Data

What does Alexza Pharmaceuticals Inc do?

Who are the key executives at Alexza Pharmaceuticals Inc?

J Kevin Buchi is the director of Alexza Pharmaceuticals Inc. Other key executives at Alexza Pharmaceuticals Inc include director & President & CEO Thomas Braxton King , Former SVP & CFO & Secretary Mark K Oki , and EVP & Operations & COO Robert A Lippe .

Alexza Pharmaceuticals Inc (ALXA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alexza Pharmaceuticals Inc (ALXA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alexza Pharmaceuticals Inc (ALXA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alexza Pharmaceuticals Inc (ALXA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alexza Pharmaceuticals Inc Insider Transactions

No Available Data

What does Stemline Therapeutics Inc do?

Who are the key executives at Stemline Therapeutics Inc?

J Kevin Buchi is the director of Stemline Therapeutics Inc. Other key executives at Stemline Therapeutics Inc include Chief Operating Officer Kenneth Hoberman , and Chief Medical Officer Eric K Rowinsky .

Stemline Therapeutics Inc (STML) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Stemline Therapeutics Inc (STML) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Stemline Therapeutics Inc (STML) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Stemline Therapeutics Inc (STML)'s detailed insider trading history can be found in Insider Trading Tracker table.

Stemline Therapeutics Inc Insider Transactions

No Available Data

What does EPIRUS Biopharmaceuticals Inc do?

Who are the key executives at EPIRUS Biopharmaceuticals Inc?

J Kevin Buchi is the director of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .

EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

EPIRUS Biopharmaceuticals Inc Insider Transactions

No Available Data

What does TetraLogic Pharmaceuticals Corp do?

Who are the key executives at TetraLogic Pharmaceuticals Corp?

J Kevin Buchi is the director & President & CEO of TetraLogic Pharmaceuticals Corp. Other key executives at TetraLogic Pharmaceuticals Corp include other: See Remarks Hudson Bay Capital Management Lp , other: See Remarks Lazard Asset Management Llc , and other: See Remarks Nomura Holdings Inc .

TetraLogic Pharmaceuticals Corp (TLOG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TetraLogic Pharmaceuticals Corp (TLOG)'s detailed insider trading history can be found in Insider Trading Tracker table.

TetraLogic Pharmaceuticals Corp Insider Transactions

No Available Data

What does Ampio Pharmaceuticals Inc do?

Who are the key executives at Ampio Pharmaceuticals Inc?

J Kevin Buchi is the director of Ampio Pharmaceuticals Inc. Other key executives at Ampio Pharmaceuticals Inc include Chief Operating Officer Holli Cherevka , CFO Dan Stokely , and Chief Financial Officer Chilcott, Iii Thomas E. .

Ampio Pharmaceuticals Inc (AMPE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ampio Pharmaceuticals Inc (AMPE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ampio Pharmaceuticals Inc (AMPE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Ampio Pharmaceuticals Inc (AMPE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ampio Pharmaceuticals Inc Insider Transactions

No Available Data

J Kevin Buchi Mailing Address

Above is the net worth, insider trading, and ownership report for J Kevin Buchi. You might contact J Kevin Buchi via mailing address: 41 Moores Road, Frazer Pa 19355.

Discussions on J Kevin Buchi

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.